Menu Search
Equities

Aixcrypto Holdings Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
7R90:MUN

Aixcrypto Holdings Inc

Actions
  • Price (EUR)4.80
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change--
  • Beta0.3489
Data delayed at least 15 minutes, as of Nov 04 2024 07:11 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

AIxCrypto Holdings, Inc., formerly Qualigen Therapeutics, Inc., is focused on building an ecosystem that integrates Artificial Intelligence (AI) and blockchain, bridging Web2 and Web3. This ecosystem unites a decentralized protocol, distributed network, AI DePIN and EAI RWA value regeneration, and a DeAI Agent product and technology platform designed to achieve optimal trading performance. Its core products include the BesTrade DeAI Agent and the AIxC ecosystem products. Its crypto business, CXC10, is centered on three growth engines which include six key products: C - Crypto 10 (C10) as Value Anchor, X - DeAI Agent, and C - RWA & Ecosystem Tokens. C - Crypto 10 (C10) as Value Anchor - through the C10 Digital Asset Treasury, C10 Index, and a potential C10 ETF. C - RWA & Ecosystem Tokens - including the C10 Stablecoin and the EAI + Crypto Dual-Bridge Real World Asset product, bridging traditional assets with Web3. It also develops and commercializes oncology and immunology therapies.

  • Revenue in USD (TTM)0.00
  • Net income in USD-8.09m
  • Incorporated2008
  • Employees4.00
  • Location
    Aixcrypto Holdings Inc5857 Owens AvenueCARLSBAD 92008United StatesUSA
  • Phone+1 (760) 452-8111
  • Fax+1 (310) 919-1600
  • Websitehttp://aixcrypto.ai/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.